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The National Cancer Institute clinical cooperative groups have been instrumental over the
past 50 years in developing clinical trials and evidence-based process improvements for
clinical oncology patient care. The cooperative groups are undergoing a transformation
process as we further integrate molecular biology into personalized patient care and move
to incorporate international partners in clinical trials. To support this vision, data acquisition
and data management informatics tools must become both nimble and robust to support
transformational research at an enterprise level. Information, including imaging, pathology,
molecular biology, radiation oncology, surgery, systemic therapy, and patient outcome data
needs to be integrated into the clinical trial charter using adaptive clinical trial mechanisms
for design of the trial. This information needs to be made available to investigators using
digital processes for real-time data analysis. Future clinical trials will need to be designed
and completed in a timely manner facilitated by nimble informatics processes for data
management.This paper discusses both past experience and future vision for clinical trials
as we move to develop data management and quality assurance processes to meet the
needs of the modern trial.
Keywords: radiation oncology, quality assurance, oncology clinical trials, National Cancer Institute, Clinical Trials
Cooperative Group Program
INTRODUCTION
In the past 50 years, the National Cancer Institute (NCI) Clinical
Trials Cooperative Group Program has generated an extraordi-
nary legacy of ground breaking clinical and translational science;
signiﬁcantly inﬂuencing the standard care for oncology patients.
As cancer therapy became more universally available in the mid-
twentieth century, oncology specialists began discussing standards
of care and how these standards could be applied in a multi-
institution cooperative group format. Pre-conceived beliefs in
treatment standards coupled with institution bias often limited
successful uniform clinical trial execution. Over time, the concept
of multi-institution clinical trial strategies matured into successful
federally funded programs. The development and maturation of
systemic therapy extensively inﬂuenced the importance and status
of cooperative group clinical trials. Only multi-institution trials,
with large study populations, could validate the role of new sys-
temic chemotherapy strategies including dose and dose scheduling
in a timely manner. Participation in clinical trials enhanced
the public perception of both large and small institutions as
participation suggested that the oncology skill set of the treatment
program functioned at a high level. Clinical faculty functioned as
clinical trial investigators and trial participation became impor-
tant and inﬂuential in institution promotion processes. Financial
incentives for trial participation provided the management infras-
tructure for the institutional trial ofﬁces. Although reimbursement
did not cover full trial costs, ﬁnances from clinical trials were used
to promote and facilitate participation in the clinical trials pro-
cess. The cooperative group administrative structures matured as
trials becamemore complex. Integration of privately and federally
funded trial processes for the adult and pediatric groups have facil-
itated therapy development as clinical trials have served to validate
treatment strategies. Enrolling over 25,000 patients yearly through
the cooperative groups, theNCI Clinical Trials Cooperative Group
Program was considered a clear and unambiguous success.
Self-renewal and re-evaluation have affected the clinical tri-
als process. While recognizing the success of the clinical trials
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program, the Institute of Medicine (IOM) report of 2010 identi-
ﬁed the need for change (Institute of Medicine of the National
Academies, 2010). The report indicated that trials processes
were too extended with imbedded system redundancies requiring
streamlining of the trial development process and strategy. The
result will be a 50% decrease in the number of cooperative groups
with new emphasis on international participation and trial devel-
opment through cancer center mechanisms. This will provide an
economy of scale for phase 3 trials and enhanced efﬁciencies for
completing phase 1 and 2 trials including adaptive mechanisms
for study execution. An effort will be made to limit the global
cost of trial development while increasing institution reimburse-
ment for execution. These are clear and bold objectives designed
to enhance thoroughness and efﬁciency. More than 50% of ple-
nary discussions at ourmost important national and international
meetings are generated from the outstanding clinical trials work.
Nevertheless, change is upon us and our success will be measured
and determined by how we adapt to the altered environment.
Accordingly, quality assurance (QA) in the cooperative groups
will be revised. QA processes have evolved becoming a robust
enterprise ﬂuent in protocol development, credentialing, data
acquisition, management, transfer, and international real-time
digital imaging and radiation therapy (RT) object data review and
feedback. Each of the QA groups, including the imaging and RT
components of study groups, has approached credentialing and
QA activities in various ways and each has achieved the similar
outcomes. Developing these programs have been important and
will continue to be important in this new network which will be
renamed the Imaging/Radiation Oncology Core Group (IROC).
This group will be administered by the American College of Radi-
ology (ACR) and integrate the imaging strengths of the ACR core
lab of theACR ImagingNetwork (ACRIN), the imaging core lab of
the Cancer and Leukemia Group B (CALGB) at Ohio State/Wright
Imaging Center, the Quality Assurance Review Center (QARC),
and the radiation oncology strengths of the Radiological Physics
Center (RPC), the Image-Guided Therapy Center (ITC;Washing-
ton University, St. Louis), the Radiation Therapy Oncology Group
Core Lab (RTOG QA Center), and QARC.
PROTOCOL DEVELOPMENT
The QA centers have developed standardized RT protocol tem-
plates based upon the radiation technology needs and protocol
objectives. Early involvement in the protocol development pro-
cess enables timely discussion of the required credentialing, data
items to be collected and imaging/radiotherapy review(s) to be
performed. Continued collaboration with the imaging and RT
committees in each cooperative group is critical to producing a
well-writtenprotocol at the initiationof a clinical trial thatwill efﬁ-
ciently and cost-effectively answer the study questions. Members
of the QA centers participate in all discipline and disease-based
committees of the cooperative groups in order to facilitate the
incorporation of QA processes into the clinical trial charter. Mem-
bers of the QA centers maintain strong relationships with both
administrative and data management cores of each cooperative
group in order that QA processes are imbedded in the clinical trial
charter. The NCI review of the protocol is thorough and serves to
further promote consistent standards for QA.
CREDENTIALING
RT CREDENTIALING
Credentialing institutions for participation in clinical trials has
been a cornerstone feature of the QA process for decades and will
remain very important moving forward. RT credentialing began
as a process to validate the physical dose delivered on each therapy
unit and provided a planning test case (benchmark) generic to
each protocol. The intent was and remains to ensure that planning
and treatment delivery can be uniform and consistent with stan-
dards. As treatment technologies and therapy execution became
more complex, credentialing mechanisms have likewise adapted
to meet this need including strategies for disease-based intensity
modulation, motion management, and radiosurgery to multiple
targets. Contrary to the opinion of those less involved with the QA
process, the IROC centers in both imaging and RT have integrated
their efforts well over the past several years providing seamless cre-
dentialing in physical dose, image fusion, target volume deﬁnition,
and advanced technology treatment execution. Moving forward,
these processes will need to become fully transparent to the clinical
trials enterprise with each new cooperative group participating in
the credentialing process in a symbiotic and synergistic manner.
Each cooperative group will have slightly different needs for cre-
dentialing and thus a tiered system will likely be used speciﬁc for
each protocol moving forward. In studies where RT is part of the
study but not a speciﬁc study endpoint, credentialing may be at
a level commensurate with the technology needed for the study.
For example, a lung cancer study in SWOG may require intensity-
modulated RT (IMRT) credentialing validation coupled with a
motion management questionnaire along with image credential-
ing for positron emission tomography/computerized tomography
(PET/CT) fusion into radiation planning computer tomography.
This will be a different mechanism than a multi-group trial evalu-
ating the use of stereotactic RT lung and liver metastasis that will
require more advanced and highly treatment speciﬁc credential-
ing for motion management. IROC will need to work with each
cooperative group to facilitate a credentialing strategy that meets
the speciﬁc needs of each protocol without limiting study accrual
objectives. Pediatrics will remain unique and likely require more
real-time review of objects and treatment plans as even experi-
enced treatment teams appreciate validation of plan intent for
study compliance. Pediatric patients are treated in a geographi-
cally diverse manner with each cancer center treating a limited
number of patients in each disease site every year; therefore, with
the exception of phase 1 and technology-speciﬁc protocols, it will
remain less likely that a limited institution study can be performed
in the pediatric community, especially in the ﬁeld of rare tumors.
IMAGING CREDENTIALING
American College of Radiology Imaging Network has provided
a strong infrastructure in developing a credentialing strategy
for radiology and the cancer centers using multiple technolo-
gies including both metabolic and anatomic imaging tools. The
CALGB imaging core service has a credentialing strategy in align-
ment with ACRIN and has provided very good data on PET QA in
clinical trials. Pediatrics will bring a separate problem set for cre-
dentialing including accelerated imaging needs in ultrasound and
magnetic resonance (MR) that will be managed with the imaging
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committee of the Children’s Oncology Group (COG). Metabolic
imaging including spectroscopy and dynamic contrast technology
are under evaluation in clinical trials and may become important
biomarkers in selected disease-based programs. ACRIN and the
CALGB imaging core center are poised and well equipped to pro-
vide a clear imaging credentialing infrastructure. Together with
QARC and the resources of the ACR, the group has considerable
strength in providing the education and infrastructure to validate
imaging interpretation and the tools to ensure study interpreta-
tions are uniform and compliant to study objectives. Similar to RT,
there is a need to establish a tiered credentialing mechanism that
may be study speciﬁc for institutions participating in clinical trials
with advanced technology imaging techniques. Potential strategies
include periodic credentialing and validation of image acquisition
processes and quality during a clinical trial.
As clinical trials move towardmore international participation,
credentialing will play a very important role. In addition to the ini-
tial credentialing, periodic re-credentialing is important aspect of
the continued QA. Currently, in RT, re-credentialing is required
when an institution/RTdepartment changes their planning system
or when a new benchmark is established for advanced technology
therapy. As we move forward and develop more precise bench-
marks to validate the contour of structures for both target volume
deﬁnition and normal tissue structures, there may be more than
one group of investigators within each institution to manage both
disease-based treatment and pediatrics. Therefore, renewing the
credentials for investigators and institutions on a periodic basis
will insure that quality processes are maintained once credentials
have been acquired.
INFORMATICS – DATA ACQUISITION/MANAGEMENT
The informatics platforms throughout the IROC are comprehen-
sive infrastructures providing the foundation for the clinical trial
support services. Currently, study data resides in the cooperative
group data centers, tissue banks, and QA centers and is integrated
as needed through each protocol and cooperative group relation-
ship. The QARC program utilizes a relational database, and is the
center of QARC’s infrastructure. Validationwas completed in 2008
making the database fully 21 Code of Federal Regulations (CFR)
Part 11 compliant. Processes and controls are in place to maintain
validation as development for new programs and technologies are
a constant. Streamlined processes enable the support of multiple
data acquisition methods. Efforts are underway within IROC to
achieve interoperability and integration of the existing informatics
systems.
CASE REVIEW
With the increasing use of advanced technology RT, there has been
an accelerated use of real-time review of both imaging and RT
treatment objects in the design and execution of clinical trials.
The objective is to insure compliance to study target volumes and
intended therapy dose as well as provide central review of imaging
objects for study execution. All current QA centers offer a mech-
anism for real-time (rapid) review of therapy objects and offer
this as a mechanism for intervention. The clinical trial beneﬁts of
real-time review have been well demonstrated by several pediatric
and adult studies (Tebbi et al., 2006; Wolden et al., 2009; Peters
et al., 2010). Real-time review accomplishes several objectives: it
establishes both a platform to review submitted information for
quality and facilitates compliance to study objectives including
clinical stage. This ensures that the patient is eligible for the speci-
ﬁed study and that the data are complete and can be used for trial
analysis. The review can identify incomplete datasets and provide
corrective action prior to patient treatment (Figures 1 and 2).
Real-time and interventional review is criticized at multiple
levels. Those outside of the clinical trials system suggest that pro-
cesses developed for real-time review are far too elaborate and do
not reﬂect actual clinical practice. There is an assumption that
deviations on study will be evenly distributed across study arms
and, accordingly, deviations will not inﬂuence study outcome. We
have seen many examples in both pediatric and adult studies that
clinical trial deviations have direct consequence on trial outcome
and deviations in image interpretation and RT can have profound
impact on studies where neither imaging or RT were the study
endpoints. The inﬂuence of real-time review may not be obvious
to a casual observer; however, the impact on clinical trial execu-
tion can be profound. A retrospective review of image objects at
the time of relapse in a high-risk pediatric medulloblastoma trial
revealed a number of patients with reported relapse/progression
actually had changes most compatible with treatment effect, not
relapse. Further more than 10% of the patients enrolled are con-
sidered ineligible due to artifacts (motion) or limitations in spinal
imaging. Accrual objectives are negatively inﬂuenced by ineligi-
ble patients and there is a cost associated with ineligible patients.
Real-time intervention can limit patients lost to study process and
serve to improve trial objectives.
Resources for real-time review of clinical trial objects will
need to be thoughtfully applied. Drawing upon lessons learned
there is a relationship to the introduction of new technologies or
applied technologies with study deviation. In the Wilms’ tumor
experience, it was not anticipated that image fusion or applied
three-dimensional RT treatment objects would be difﬁcult for
the clinical trials community to assimilate into the clinical tri-
als process. However, radiation oncologists have not been able to
make the needed adjustments using modern planning tools in a
treatment area that historically has been approached with estab-
lished two-dimensional treatment strategies. In the HeadSTART
trial, we saw deviation patterns consistent with uncertainties in
the application of imaging objects into RT treatment planning
systems (Figure 3). As time evolves, these issues are addressed
through both the clinical trials process and clinical experience.
History has shown that as investigators become familiar with
disease-based protocol applications and consistent in executing
clinical trial objectives, new technologies, and advanced imag-
ing strategies are introduced into clinical trials that will require
intervention to make certain they are applied in a protocol com-
pliant manner. Intensity modulation and motion management
are two very good examples where varied technologies need to
be applied in a uniform manner for protocol compliance. The
process of intervention permits uniform application of these tech-
nologies in a protocol compliant manner. Although we casually
perceive these tools as the standard of care, from a clinical trials
perspective we are not at a point of development where we can
simply assume without intervention that these tools are used in
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FIGURE 1 | Case submitted for interventional review demonstrating necessary volume revision.
FIGURE 2 | Case submitted for interventional review in Figure 1 demonstrating improved dose coverage.
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FIGURE 3 | Overall survival by deviation status. Figure as originally
published in Peters et al. (2010).
a uniform clinical trial manner. In fact, evidence suggests oth-
erwise. Our technologies allow us to re-invent our treatment
strategies on a constant basis. The process of re-invention is
diverse, complicated by varied therapy technologies and tech-
niques supported through multiple vendors. QA processes and
a real-time intervention strategy permit the appropriate degree
of QA, and facilitate the assimilation of diverse platforms into
a common treatment execution strategy. As platforms and dis-
ease treatment strategiesmature and treatment paradigms become
more consistent, adjustments can be made in the QA process to
place emphasis and resources in new areas of development and
examine potential controversy. In collaboration with the imag-
ing and RT committees of each new cooperative group, the newly
formed QA center will need to anticipate the likelihood for real-
time intervention and write these requirements into the clinical
trial charter as part of clinical trial development. It remains easier
and more cost-effective to anticipate this need rather than react
to an unanticipated development after a trial has been activated.
Each clinical trial with RT will likely have an assigned category for
real-time review, dose validation, contouring, and motion man-
agement. There will likely be trials that focus on credentialing with
data collection and no real-time intervention. Others, including
trials with developing technologies or difﬁcult contouring chal-
lenges, may place heavy emphasis on real-time review of objects.
These and other processes will be debated through committee and
included as part of the clinical trial charter. Having established
these points, there will need to be processes in place during the
clinical trial operation to insure that the chosen strategy for QA
is fulﬁlling the objectives of the study. This will be an on-going
process of self-renewal and lessons learned from adaptive mech-
anisms that can be built into the next iteration of the clinical
trial.
A secondary beneﬁt to real-time interventional review is the
fact all of the data can be reviewed at the time of patient treatment
and incomplete records can be completed as part of that process.
HISTORY AND LESSONS LEARNED
EARLY RT QA
Quality assurance has always played a unique role in the clinical
trials enterprise. The early contributions of radiation oncology
medical physicists working closely with their clinician colleagues
led to the development of radiation treatment QA programs that
are unparalleled by other medical specialties involved in clinical
trials. These early protocols that used radiation for therapy led
to rigorous QA and educational programs. Compliance systems
were established to verify the radiation doses received by protocol
subjects and assure the participating institutions and investigators
understood the technical demands for protocols that incorporated
new radiation dose delivery technologies (D’Angio, 1980; Galvin
et al., 1980; Kim et al., 1980). More recently, credentialing meth-
ods have been introduced to verify performance of the protocol
components. A system has evolved to ensure common ground in
protocol execution and to create uniform study populations for
study outcome validation.
Quality assurance implies the appropriate diagnosis and stag-
ing are obtained and meet protocol standards, patient studies
are acquired and interpreted in a uniform format, and the treat-
ment is conducted in a protocol compliant manner. QA processes
have changed over the 50 year cooperative group history. For
the cooperative groups that originated in 1960/1970, retrospective
reviews were done with hard copy data and images. There was no
deﬁned role for review intervention prior to therapy execution. RT
study deviations were largely computational as there was a non-
uniform approach to treatment calculation and no images were
available to validate the target volume. Initially it was difﬁcult to
obtain the data and images. Over time clinical trials required data
review as part of the study conduct. The timeliness and quality
of data submitted for review were incorporated into institutional
performance review.
In the early days of clinical trial development, retrospective data
review was important but had clear limitations. Communication
capabilities were not as sophisticated as they are currently, and
the data inﬂuenced in the processes written for the next genera-
tion of trials made no immediate contribution to the active study.
The knowledge gained from the clinical trial data reviews includ-
ing lessons learned from study deviations was only recognized
through generations of subsequent trials. The processes would, by
default, unintentionally promote signiﬁcant misinterpretation of
study outcome (Weiner et al., 1997; Kachnic et al., 2011; Abrams
et al., 2012).
LESSONS LEARNED
A retrospective review of the Pediatric Oncology Group (POG)
Protocol 8725 data objects, which included review of images
demonstrating the sites of disease at presentation and review of
RT treatment objects, revealed a statistically signiﬁcant survival
advantage to patients treated with RT in a protocol compli-
ant manner (FitzGerald et al., 2008). This review conﬁrmed that
RT treatment delivered in a protocol compliant manner affected
patient outcome (Figure 4).
From that point forward, efforts were made in most coopera-
tive groups and QA centers to incorporate real-time object review
into the QA process as often as possible and reasonable (Schwartz
www.frontiersin.org March 2013 | Volume 3 | Article 31 | 5
“fonc-03-00031” — 2013/3/15 — 11:36 — page 6 — #6
FitzGerald et al. Oncology clinical trials QA vision
FIGURE 4 | Pediatric Oncology Group (POG) Protocol 8725 Survival
according to treatment. Figure originally published in FitzGerald et al.
(2008).
et al., 2009). For POG and then the COG, real-time RT object
review became standard practice for clinical trials involving RT in
Hodgkin’s lymphoma (HL).
Continued progression of real-time reviewwas evident in COG
clinical trials 9425 and 9426 (HL high/low risk, respectively),
where compliance for RT review pre-therapywas outstandingwith
a profound decrease in the RT study deviation rate (Tebbi et al.,
2006; Schwartz et al., 2009; Figure 5).
These risk adaptive studies required the QARC to acquire the
diagnostic images for response as part of the RT pre-treatment
review. The concordance rate for response between site and central
review was 50%, implying a clear need to integrate central review
of image objects into the real-time review process. Accordingly,
intermediate risk HL COG protocol AHOD0031 incorporated
real-time review of diagnostic images for response as well as pre-
treatment review of RT objects. Secondary and tertiary study
randomization points were based on real-time central review of
objects (Wolden et al., 2009; Figure 6). Currently open high-
risk HL protocol AHOD0831 extends the process further as only
selected sites of involvement that do not completely respond
to chemotherapy undergo RT. Recent review of RT data from
AHOD0031 conﬁrms that pre-treatment review of RT treatment
objects can signiﬁcantly limit deviations on study (Dharmarajan
et al., 2012a,b).
The evolution of real-time review strategies for diagnostic radi-
ology and radiation oncology has been the culmination of process
improvements in digital imaging and RT data transfer. The ACR
through the RTOG and the ACRIN has made extraordinary con-
tributions to the efforts of digital data transfer with digital transfer
systems and web-based media for institutional credentialing and
clinical trial conduct. ACRIN has successfully managed individ-
ual clinical trials accruing more than 50,000 patients per trial
with advanced technology imaging for breast, lung cancer, and
glioblastoma studies, aswell as additional signiﬁcant contributions
to the other cooperative groups. In collaboration with members
of the ITC, the RTOG has provided the infrastructure for dig-
ital radiation oncology data transfer as well as the institutional
credentialing mechanisms with the RPC. These mechanisms have
served to promote the process and availability of real-time object
FIGURE 5 | Evolving review paradigm for pediatric HD trials.
review to ensure the images and intended treatment plan are study
compliant. The CALGB imaging core center likewise maintains a
very similar process.
In spite of the clear success of these processes, including
real-time reviews, and the improvements offered to clinical trial
investigators, there is a perception that the overall QA process is
expensive, excessive, and often unnecessary. Arguments are made
that attempts to eliminate deviations confound clinical care as the
process does not reﬂect the activities of daily clinical practice and
deviations will be equally distributed among all arms, therefore
not affecting study outcome. There are arguments to the contrary.
The data suggest that patient outcome and uniform treatment
delivery on study is likely best served by creating QA systems that
ensure protocol compliant treatment strategy prior to treatment
delivery. Through a multifaceted approach that incorporates edu-
cation, credentialing and reviews, QA strategies can be tailored to
the requirements of a particular protocol.
The recent and current COG Wilms’/renal studies provide
examples of how pre-determined processes can provide clear
direction for study success as well as opportunities for pro-
cess improvement. As in most modern clinical trials, there are
several endpoints imbedded into trial objectives. Patients are
stratiﬁed into low-, intermediate-, and high-risk groups. High-
risk patients with pulmonary nodules at presentation are treated
with chemotherapy. Pulmonary images at presentation and week
6 of therapy are centrally reviewed through digital media in
real time. If there is a complete response deﬁned by central
review, patients do not receive pulmonary RT. This process has
worked exceptionally well and all follow-up images are collected
for outcome analysis. Interestingly, there has been an unantici-
pated issue with anatomical distortion generated by the primary
renal disease in the fused CT/planning studies requiring sagittal
reconstruction. This has been responsible for many unanticipated
RT deviations as traditional anatomic radiation treatment guide-
lines appear less consistent with targets deﬁnitions designed using
three-dimensional objects. Three-dimensional planning tools are
important in designing the inferior aspect of the pulmonary vol-
ume forwhole lung therapy and the fused pre-operativeCT images
successfully predict for the inferior aspect of the renal target. Mov-
ing forward, theQA strategies would include pre-treatment review
of objects and the expanded use of atlases, web-based interac-
tion tools, and real-time review of objects. Clinical trial processes
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FIGURE 6 | Real-time review points in COGAHOD0031.
need to be adaptive in nature and, as in AHOD0031, be able
to implement change during a study to insure study objectives.
Reviews of processes during clinical trials will serve to improve
study performance as adjustments are made to accommodate for
problems identiﬁed during the conduct of the study.
Altruism with the intent of cost containment can lead to
unexpected consequence and limitations in data availability. The
CALGB completed an outstanding series of breast cancer clini-
cal trials deﬁning the use of dose dense chemotherapy including
studies deﬁning the potential role of taxol in node positive breast
cancer patient care (Citron et al., 2003; Henderson et al., 2003).
In 1997, seminal publications revealed a survival advantage
to node positive breast patients receiving RT (Overgaard et al.,
1997; Ragaz et al., 1997). These and subsequent studies altered the
landscape of therapy and changed the perception of local therapy
in the treatment community. A retrospective review of patients
treated on the CALGB trials revealed an extraordinary diversity of
radiation dose and volume on patients receiving RT as there were
no speciﬁcRT guidelines imbedded into the study. Therewas also a
trend for patients who received taxol to have been treated with RT,
thus complicating study interpretation. The retrospective review
of data was difﬁcult to accomplish as the primary trial objectives
had been met and only limited data sets could be collected in
retrospect as many patient ﬁles at participating institutions had
been relocated and stored in various formats with limited retrieval
capability. If data sets were collected as part of the protocol (not
necessarily reviewed but stored), we would have been able to query
the data and review the information in a timely manner (Sartor
et al., 2005).
More recent events have further promoted the potential impor-
tance of breast cancer volumetric datasets. In the past several years
multiple studies have addressed the question of the importance
of axillary staging and therapy. National Surgical Adjuvant Breast
and Bowel Project (NSABP) study B32 evaluated breast cancer
patients treated with either axillary dissection or sentinel lymph
node staging procedures and demonstrated thatmore limited axil-
lary surgery with sentinel staging had equivalent patient outcome
to axillary dissection. ACOSOGprotocol Z0011demonstrated that
more extended axillary surgery may not be indicated even in node
positive patients receiving RT. Study MA-20 conducted by NCI-
Canada demonstrated the statistical importance of regional RT in
node positive breast patients.
These studies all point to important issues in radiation oncol-
ogy. However, no study collected volumetric treatment data.
Modern radiation oncologists need to establish common ground
as to how they will contour axillary structures and agree upon
techniques for therapy to cover the volume, provide conformal
avoidance to structures such as the axillary vessels and brachial
plexus, and limit sequelae from radiation management. If volu-
metric RT treatment data were submitted on these studies coupled
with outcome imaging from relapse, radiation oncologists could
review these data and adjudicate strategies for RT protocol design
moving forward. In three-dimensions many of the lymph node
volumes at risk are in the anterior plane and often partially treated
in breast ﬁelds. However, the posterior axilla abuts the latis-
simus muscle and data from the University of Florida does suggest
regional control is improved in patients with additional posterior
ﬁelds (Chang et al., 2007).
Our challenge in this time of ﬁnite resources will be to ensure
data integrity for future analyses and to do this within the conﬁnes
of deﬁned resources. Gathering data for the future has a cost in
terms of simple things similar to checking data integrity to make
sure that the data will be useful at a later point in time.
EDUCATION
The clinical trial QA programs assure quality and implement
quality improvement (QI). These strategies include face to face
and on-line workshops and training; on and off-site audits;
web-based learning modules, resources, and tools; and fellow-
ships. The QA centers provide education to a varied audience
www.frontiersin.org March 2013 | Volume 3 | Article 31 | 7
“fonc-03-00031” — 2013/3/15 — 11:36 — page 8 — #8
FitzGerald et al. Oncology clinical trials QA vision
including the public, patients, researchers, and research staff.
Providing on-going education for clinical researchers and staff
strengthens the research and is an aspect of the International Con-
ference on Harmonisation (ICH) good clinical practice quality
standard.
QUALITY ASSURANCE OF FUTURE CLINICAL TRIALS
Quality assurance for future clinical trials will seamlessly incor-
porate imaging, RT, pathology, and patient outcome data likely
with a common informatics platform. The current QA centers
will integrate under a uniﬁed global structure for imaging and RT.
Four guiding principles for QA and informatics cooperative group
support have been established. These principles are: (1) The QA
process includesmultiple activities starting with protocol develop-
ment and including assessments of institutional capabilities and
data quality; (2) Harmonization of QA processes and standards is
needed to improve the efﬁciency and effectiveness of the QA pro-
cess across the cooperative group network; (3) The IT systems that
support imaging and RT QA should be interoperable and com-
pliant with existing standards for protecting patient privacy and
ensuring data integrity; and (4) Imaging and RT data collected in
theQAprocess are important scientiﬁc resources. From the lessons
learned, the QA processes and QI tools will be enhanced to pro-
mote efﬁciency and effectiveness. The funding source for this new
QA system will originate from a single source independent of a
speciﬁc cooperative group. Tissue banks will be funded separately,
however, there is an expectation that digital pathology objects will
be linked into review systems to expedite new biomarkers.
Imaging/Radiation Oncology Core Group will move toward
building a fully integrated system that includes all of the current
organizations in this QA system. Each of these organizations has
their own software, work processes, and procedures in place. Inno-
vation will come fromwithin the group. Each of the IROC entities
has functioning systems designed for the services and studies they
support. To the outside world, these appear redundant; Insid-
ers would likely argue that although they appear similar, they are
uniquely designed and processes have been built around them so
that each entity functions efﬁciently. Initially, these systems will
be left in place and interoperability will be established with the
goal of empathy with user requirements (usercentric). With a user
friendly interface the investigator will be able to submit data and
receive a receipt that the data reached its destination complete and
not corrupted. Today’s technologies yield a rich array of possibili-
ties for collaboration and data exchange that can be maximized to
support the heterogeneous community of clinical trial participat-
ing sites. Thus it is important to support all commonly accepted
data acquisition and exchange strategies. It is relatively straightfor-
ward to take any of the common strategies and build functionality
into it that validates the data and brings it into an organization’s
legacy system for further processing, review and archiving. In the
case of QARC, there is the MAX database which functions as an
operating system for the QARC staff and for the off-site reviewers
who review clinical trial data from remote sites. Aswemove toward
integration, each center will contribute their imbedded strength
in informatics to a common platform.
The single portal with a friendly, functional interface bene-
ﬁts the user with one site for data submission. They can submit
data using various “standard” transfer mechanisms at ﬁrst and
more sophisticated systems as the site develops. Investigators will
access a single secure portal; identify their target organization and
transmission method prior to the data submission. They will be
informed immediately whether the data transfer was successful.
This same interface will notify the target organization of data wait-
ing to be further validated and utilized. The organization assigned
to process, manage and/or review the data will retrieve it, verify
that it is not corrupt and that it is the correct data for the particular
protocol requirements. The data will then be available to import
for processing and export to a shared repository. This will allow
partner organizations to have access to the data immediately and
will eliminate redundant processes.
Investigatorswill have access to the integrated database for eval-
uation of clinical trial objects. During the course of a clinical
trial, data will be protected with limited access through traditional
mechanisms established by the cooperative groups. Once trials
are closed and the data statute of limitations is established, de-
identiﬁed data can bemade available to national and international
investigators for secondary data analyses.
EVALUATE AND PARTICIPATE IN NEW OPPORTUNITIES
Many clinical trial participants point toward redundancies in
process and data submission as barriers to clinical trials involve-
ment. Although credentialing centers such as theRPC,RTOG/ITC,
ACRIN,andQARChaveworkedwell together to integrate function
and synergize credentialing mechanisms, investigator perceptions
are often inﬂuenced by these and other credentialing processes.
Due to the issues and regulations in daily clinical practice, incor-
porating clinical trial objectives is perceived as a challenge. The
landscape is changing and theremay be opportunity to re-engineer
credentialing strategies in manners not previously anticipated.
This will include an expanded use of registration trials for data
collection and management.
In Massachusetts (MA), ACR credentialing is now required if a
radiation oncology system is going to manage a new and/or satel-
lite treatment facility and insurance companies are beginning to
evaluate the use of credentialing mechanisms for reimbursement
of advanced treatment technologies. Included in this strategy is a
new system of IMRT approval which requires normal tissue vol-
ume metrics for validation of the use of this technology. This
was recently approved by Blue Cross/Blue Shield of MA and sev-
eral in-state companies are reviewing this program and will likely
adopt this and other similar reimbursement strategiesmoving for-
ward. This may provide institutional incentive for credentialing
as the process of credentialing could serve more than one pur-
pose. A synergistic strategy could be put into place to use the
identical credentialing strategy to perform multiple functions.
For example, approval of the RPC for beam output (optically
stimulated luminescent dosimeter/thermoluminescent dosimeter,
OSLD/TLD) measurement coupled review of department pro-
cesses by the ACR/American. Society for Radiation Oncology
(ACR-ASTRO) including remote case review would permit recip-
rocal credentialing for low tier participation in the clinical trials
process. This can be expanded to sub-specialty based practice
including pediatrics, gynecology, and others on an as-needed basis
with periodic re-credentialing as appropriate. The tools currently
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in use and to be developed by the QA center would be an invalu-
able resource to this process in development. They would establish
a nimble and potentially interactive infrastructure for credential-
ing and validating dose volume metrics for IMRT and advanced
technology treatment delivery as well as the real-time review. This
could serve to both credential institutions for clinical trials partic-
ipation and validate the credentialing process for ACR and other
regulatory agencies. This could mature into a tiered strategy with
RT-speciﬁc questions requiring more rigorous review by the QA
centers including dose/volume review with motion management.
The opportunities for process improvements in cancer care are
boundless working in concert with an integrated IT platform.
Building an integrated IT network including pathology will
permit evaluation of other opportunities perhaps even beyond
oncology. Many disciplines, including cardiology, critical care,
neuroscience, etc. will beneﬁt from integrated platforms includ-
ing imaging and patient outcome data. Experts in late effects and
many associated with the developing area of interventional oncol-
ogy will be able to use integrated platforms joined with data from
molecular oncology leading to discovery and the development of
novel treatment strategies including the international community.
This is a leadership moment for all involved and an opportunity
to build a system that can lead and deﬁne the cancer care man-
agement of the future. Building upon the established strengths of
the current QA systems, an integrated informatics and QA plat-
form can be built to make the entire clinical trials program greater
than the sum of the parts and serve the oncology clinical tri-
als community by facilitating processes required for clinical trials
execution.
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